Poster: High-throughput immune complex analysis method for CAR T cell-mediated cytotoxicity using the Celigo Image Cytometer

Download our Poster Abstract: Cancer immunotherapy has been gaining momentum in the field of cancer research. Specifically, Chimeric Antigen Receptor (CAR) T cell technology have introduced new methods to combat cancer. Direct cell-mediated cytotoxicity assays are required to assess the killing capability of the engineered CAR T cells. Traditionally, these assays are conducted by measuring the amount of released Chromium, calcein AM, or LDH molecules after the target cancer cells are killed with CAR T cells. These methods require a large amount of target cells which may not be ideal when working with donor primary samples. Additionally, they cannot [...]

By | 2018-06-21T14:01:23+00:00 April 5th, 2018|Categories: Celigo Application News, Latest News|Tags: , , , |0 Comments

High throughput, high-resolution image acquisition for DNA damage detection

Celigo playing an important role in high throughput, high-resolution image acquisition for DNA damage detection. The Celigo S captures 16 images of each well that are then stitched into a single representation Open access article: Next generation high throughput DNA damage detection platform for genotoxic compound screening

By | 2018-06-15T15:35:51+00:00 March 2nd, 2018|Categories: Celigo Application News, Latest News|Tags: , , , |0 Comments

Celigo Helping Move Research Forward to Find a Cure for Alzheimer’s

November is National Alzheimer's Disease Awareness Month and research into a cure for the disease is vigorous. In a recently published paper "CRISPR/Cas9-Correctable mutation-related molecular andphysiological phenotypes in iPSC-derived Alzheimer’s PSEN2N141I neurons" researchers used the Celigo image cytometer upstream of CRISPR/Cas9 to visualize and asses cell death related to the sensitivity of iPSC-derived PSEN2N1411 neurons in the presence of Aβ42 oligomer toxicity.

By | 2017-11-07T10:53:34+00:00 November 7th, 2017|Categories: Celigo User Publications|Tags: , , , |0 Comments

Benefits of direct high-throughput cell counting in immuno-oncology research

Antibody-directed and drug therapies have been on the forefront of immuno-oncology research in the past 15 years. Since the FDA introduced the Breakthrough Therapy Designation in 2016 for novel promising drug therapies, the number of applicants and approved candidates has increased dramatically. As more and more researchers are looking at drug effects in cancer cells and moving forward in drug discovery, they face many challenges in their day to do work. Performing cell cytotoxicity assays for multiple cell lines with single and combination drug therapies is standard practice in immuno-oncology. While many researches use end-point assays such as MTT, XTT, WST, or CellTiter-Glo, others prefer the manual [...]

Celigo 5 Channel system officially released

Lawrence, Massachusetts – September, 2016 - Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced it has released the addition of a 5th channel available as an option on the Celigo image cytometer. The Celigo is a bench-top image cytometry system providing whole-well imaging and quantitative data, through image analysis for demanding cell-based analytical applications. Previous configurations allowed bright field only imaging, or bright field imaging plus 3 fluorescent channels. This new option of bright field plus 4 fluorescent (red, green, blue and far-red) channels will allow researchers more capabilities [...]

By | 2016-09-08T16:30:19+00:00 September 8th, 2016|Categories: Celigo Application News|Tags: |0 Comments

Celigo assists in optimizing CHO cells for biopharmaceutical production

The Novo Nordisk Center for Biosustainability (Denmark) set out to improve the efficiency of Chinese hamster ovary (CHO)-cell based production of non-monoclonal antibody, therapeutic glycoproteins designed to serve as biopharmaceuticals. To optimize the growth and production capacities of these CHO cells, the scientists looked at: lipid-based transfection, cell cultivation, cell counting, and antibody-independent product titer. Different growth and transfection parameters were investigated to see which yielded the highest growth profiles and production capacities. The Celigo was used in combination with Hoechst and propidium iodide to count the cells in 96-well format. The system developed here miniaturized the process and allowed [...]

Celigo evaluates quinomycin A as a possible therapeutic tool for pancreatic cancer

The Notch-disrupting and cancer stem cell-inhibiting effects of the drug quinomycin A were investigated at the University of Kansas Medical Center. Using human pancreatic cancer cells PanC-1, MiaPaCa-2, and BxPC-3 and the Celigo to determine the number and size of pancreatospheres, researchers evaluated the drug’s ability to block cancer stem cell growth via inhibition of the Notch signaling pathway. After administration of the drug, proliferation and colony formation were blocked in cancer cell lines but not in normal pancreatic epithelial cells. Furthermore, cancer stem cell markers were reduced as was pancreatosphere formation. This work identifies quinomycin A as an efficacious [...]

By | 2018-06-11T14:49:57+00:00 January 26th, 2016|Categories: Celigo User Publications|Tags: , |0 Comments

Celigo furthers studies of homologous recombination DNA repair machinery

The Danish Cancer Society Research Center recently published a study furthering their analysis of homologous recombination DNA repair machinery. The group previously reported on a growth factor, PSIP1, that enables DNA end resection. With GFP-transfected U2OS cells, the group investigated a structurally similar protein, hepatoma-derived growth factor-related protein 2 (HDGFRP2). The Celigo analyzed cell number and viability via fluorescent markers. The group reports that HDGRFP2 may help to repair silent genes that have been impaired or active genes inhibited by DNA damage. Read the full publication here. 

By | 2016-01-21T10:00:39+00:00 January 21st, 2016|Categories: Celigo User Publications|Tags: , , |0 Comments

Nexcelom to hold inaugural Celigo user group meeting in London, February 2016

On February 9, 2016 at the Institute for Cancer Research, Chelsea, London, UK, Nexcelom will be holding an inaugural Celigo user group meeting, free to anyone who would like to attend. Celigo users from the pharmaceutical, academic, and biotech sectors will be present to discuss their research with this instrument. Speakers will include: Dr. Daniel Paull – NYSCF Dr. Maria Vinci – ICR Dr. Urs Senn – ETH Zurich Dr. Henning Gram Hansen – DTU Dr. Thilo Riedl – Genmab Dr. Valerie LeFourn – Selexis Dr. Christian Muller – Universite de Strasbourg The Celigo is a best-in-class image cytometer, with [...]

By | 2018-06-11T14:48:43+00:00 January 12th, 2016|Categories: General Discussions|Tags: |0 Comments

Celigo evaluates a plant extract for glioblastomoa multiforme treatment

At the Canary Center at Stanford for Early Cancer Detection, investigators studied how AshwaMAX (a steroidal lactone from a winter cherry plant, Withania somnifera, extract) might work as an oral treatment for those with the highly aggressive cancer glioblastoma multiforme (GBM). A heterogeneous disease, non-specific therapies for GBM have proven largely ineffective. Two patient-derived GBM lines (GBM2, GBM39) and one GBM cell line were cultured to create neurospheres that were then exposed to various concentrations of AshwaMAX.  Celigo measured cell proliferation and cell death via Trypan Blue staining. AshwaMAX inhibited the neurospheres at nanomolar concentrations. After additional work in vivo, [...]